Author(s):
Santos, Gilberto Maia ; Ismael, Shámila ; Morais, Juliana ; Araújo, João R. ; Faria, Ana ; Calhau, Conceição ; Marques, Cláudia
Date: 2022
Persistent ID: http://hdl.handle.net/10362/137066
Origin: Repositório Institucional da UNL
Subject(s): inflammatory bowel disease; intestinal alkaline phosphatase; intestinal barrier function; low-grade chronic inflammation; metabolic dysfunction; necrotizing enterocolitis; obesity; Microbiology; Microbiology (medical); Virology; SDG 3 - Good Health and Well-being
Description
Funding Information: This study was supported by ERDF through the operation POCI-01-0145-ERDF-007746 funded by Programa Operacional Competitividade e Internacionaliza??o?COMPETE2020 and by National Funds through FCT?Funda??o para a Ci?ncia e a Tecnologia within CINTESIS, R&D Unit (reference UID/IC/4255/2013) and (PTDC/BAA-AGR/7419/2020).
Intestinal alkaline phosphatase (IALP) has recently assumed a special relevance, being the subject of study in the prevention and treatment of certain diseases related to leaky gut. This brush border enzyme (ecto-enzyme) plays an important role in the maintenance of intestinal microbial homeostasis and intestinal barrier function through its ability to dephosphorylate lipopolysaccharide (LPS). This review addresses how IALP and intestinal barrier dysfunction may be implicated in the pathophysiology of specific diseases such as inflammatory bowel disease, necrotizing enterocolitis, and metabolic syndrome. The use of IALP as a possible biomarker to assess intestinal barrier function and strategies to modulate IALP activity are also discussed.
